UK government reserves Wockhardt production line to fill finish COVID-19 vaccines
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
List view / Grid view
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
The National Institutes of Health in the US has awarded contracts to seven biomedical companies to develop and manufacture COVID-19 diagnostics.
According to David Bennett, securing and building trust in the label, brand and process of a highly regulated industry player in a complex age will demand a new approach.
Sanofi and GSK have reached an agreement with the UK government to supply up to 60 million doses of their COVID-19 vaccine.
29 July 2020 | By Charles River
In this webinar we discuss the results of our latest study where we evaluated the ruggedness, repeatability and specificity of commercially available rFC products, as well as our own recombinant product in development, against a large panel of endotoxins.
Sandoz plans to invest €150 million and the Austrian government €50 million into integrated antibiotic manufacturing operations at Kundl.
Gilead has announced that the potential COVID-19 drug remdesivir will cost $390 per vial for developed countries, with treatment courses costing $2,340 per patient.
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
Many pharmaceutical companies have complicated supply chains that are inefficient and ill-equipped to deal with current demands. This article explores how digitalising the healthcare supply chain can address the pharmaceutical sector's increasing financial-, capacity- and waste-related strains associated with our ageing population and the soaring costs of new treatments.
As the main excipient for the pharmaceutical industry, water is integral to patient safety and the quality of pharmaceutical products.
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
Smita Deshmukh describes the current state of the global drug intermediates market, while suggesting how it will grow in the future.
According to findings, the majority of CMOs in Italy are found in the locations hit worst by COVID-19, meaning the pharma supply chain has been greatly impacted.
According to a new agreement between Mylan and Gilead, the former has the rights to manufacture and distribute remdesivir in 127 countries, a drug being tested to combat COVID-19.
A PricewaterhouseCoopers report has highlighted the directions that the growth of the contract development and manufacturing organisation (CDMO) outsourcing market will take in the near future.